MiNK Therapeutics (NASDAQ:INKT – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Volatility & Risk
MiNK Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Earnings & Valuation
This table compares MiNK Therapeutics and Tarsus Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($0.49) | -1.47 |
| Tarsus Pharmaceuticals | $17.45 million | 99.54 | -$135.89 million | ($4.48) | -10.19 |
Profitability
This table compares MiNK Therapeutics and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiNK Therapeutics | N/A | N/A | -233.85% |
| Tarsus Pharmaceuticals | -180.00% | -63.99% | -47.64% |
Analyst Ratings
This is a summary of current ratings and recommmendations for MiNK Therapeutics and Tarsus Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Tarsus Pharmaceuticals | 0 | 1 | 5 | 1 | 3.00 |
MiNK Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 1,150.00%. Tarsus Pharmaceuticals has a consensus target price of $51.60, suggesting a potential upside of 13.01%. Given MiNK Therapeutics’ higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Tarsus Pharmaceuticals.
Institutional & Insider Ownership
2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 19.7% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
MiNK Therapeutics beats Tarsus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
